




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 47/48		A2	(11) International Publication Number: WO 92/11037
			(43) International Publication Date: 9 July 1992 (09.07.92)
(21) International Application Number: PCT/US91/09368 (22) International Filing Date: 13 December 1991 (13.12.91) (30) Priority data: 630,017 19 December 1990 (19.12.90) US (71) Applicant: ADVANCED MAGNETICS INC. [US/US]; 61 Mooney Street, Cambridge, MA 02138 (US). (72) Inventors: JOSEPHSON, Lee ; 14 Churchill Avenue, Ar- lington, MA 02174 (US). GROMAN, Ernest, V. ; 80 Co- lumbia Street, Brookline, MA 02135 (US). JUNG, Chu ; 21 Coolidge Road, Arlington, MA 02174 (US). LEWIS, Jerome, M. ; 273 Upland Avenue, Newton, MA 02161 (US).			(74) Agents: SUNSTEIN, Bruce, D. et al.; Bromberg & Sun- stein, 10 West Street, Boston, MA 02111 (US). (81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European pa- tent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (Euro- pean patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), NO, SE (European patent)..
			Published Without international search report and to be republished upon receipt of that report.

(54) Title: TARGETING OF THERAPEUTIC AGENTS USING POLYSACCHARIDES



(57) Abstract

The invention relates to a method for the targeting of a therapeutic agent to a specific population of cells, wherein a complex is formed between the therapeutic agent and a polysaccharide capable of interacting with a cell receptor, and wherein the resulting complex is internalized into the cell by receptor mediated endocytosis (RME). In one embodiment of the invention, a complex of a therapeutic agent containing iron and the polysaccharide arabinogalactan may be formed and used to deliver iron specifically to hepatocytes by RME.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU ⁺	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE*	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

TARGETING OF THERAPEUTIC AGENTS USING POLYSACCHARIDES

5 Technical Field of the Invention

The present invention relates to methods for the targeting of a therapeutic agent to a specific population of cells, especially hepatocytes.

Background of the Invention

10 Before reviewing the background art, it is useful to define certain terms. A therapeutic agent is one administered with the intent of changing, in a beneficial manner, some physiological function of the recipient. Therapeutic agents include drugs, proteins, hormones,
15 enzymes, nucleic acids, peptides, steroids, growth factors, modulators of enzyme activity, modulators of receptor activity and vitamins. A diagnostic agent is one administered with the intent of illuminating some physiological function, while leaving physiological function
20 unaffected. Diagnostic agents include radioactive isotopes for scintigraphy, electron dense labels for X-ray or computer tomography, and magnetic labels for magnetic resonance imaging.

 Targeting is the modification of an agent so that after
25 parenteral administration its uptake by a specific type or population of cells is increased, over that obtained with the unmodified agent.

 Receptor mediated endocytosis (RME) is a process whereby molecules in the extracellular space bind to
30 specific receptors on the cell surface and are internalized. Through the process known as RME, molecules injected into the vascular compartment are cleared (removed) from plasma.

 Uptake by RME exhibits three general properties characteristic of ligand-receptor interactions generally:
35 structural specificity, saturability and competition. Structural specificity is observed when a receptor can distinguish between closely related structures and only molecules with structures meeting the binding requirements of the receptor binding site are internalized. Often the

- 2 -

receptors involved in RME are discovered by their ability to internalize or clear glycoproteins from circulation.

Saturability is observed when the rate of an agent internalized via RME decreases with increasing
5 concentrations of that agent. This results because, at high concentrations, the receptor approaches full occupancy or becomes saturated with ligand.

Competition is observed when the rate of internalization of an agent can be reduced by the presence
10 of additional agents bearing a structural resemblance to the first agent. The additional agents compete for receptor binding sites and decrease the rate of internalization of the first agent. Saturability results when high
15 concentrations of a single ligand compete for a limited number of receptor sites. Competition results when chemically different ligands bind to a limited number of receptor sites.

The uptake of substances by RME is a feature of normal, healthy cells. RME transport systems can be found on normal
20 macrophages, hepatocytes, fibroblasts and reticulocytes. RME enables cells to internalize a variety of macromolecules in plasma, such as asialoglycoproteins, low density lipoproteins, transferrin and insulin. See Table 1 of Wileman et al., 232 Biochem. J. (1985) pp. 1-14 for a list
25 of cells performing RME, which also contains a general review of RME. See also Table I of Menz, E.T., PCT WO 90/01295, filed August 3, 1989. Conversion of normal cells to tumor cells (transformation) may be associated with an increase or decrease in the activity of receptors performing
30 RME. In some cases, such as the RME performed by the asialoglycoprotein receptor of hepatocytes, transformation to cancerous hepatoma cells is associated with receptor loss. Stockert et al., 40 Cancer Res. (1980) pp. 3632-3634. In many cases, like the antibody based targeting of drugs to
35 tumor antigens, the antigens are increased on tumor cells and decreased on normal cells.

Polysaccharides like arabinogalactan, which interact

- 3 -

with receptors involved in RME, are referred to as RME-type polysaccharides. Many common polysaccharides such as dextrans, dextrans, celluloses, hydroxyethylstarches, heparins, starches, dextran sulfates, carboxymethylated
5 dextran and carboxymethyl cellulose do not interact with receptors involved in RME; they are referred to as non-RME polysaccharides.

With these definitions in hand, the relevant background art will be discussed. Non-RME type polysaccharides have
10 been used in the synthesis of a variety of materials used as diagnostic or therapeutic agents. Jacobsen, T., EPO O 186 947 B1; Schroder, USP 4,501,726; Ranney, D.F., PCT WO 90/03190, filed September 29, 1989; Groman, USP 4,827,945; Groman, USP 4,770,183. Ranney discloses the delivery of
15 diagnostic agents (metal ions as magnetic resonance (MR) contrast agents) using a polymeric carrier which is directed to tumor cells. Ranney suggests, without detailed examples, that other therapeutic complexes may also be delivered using this method, for chemotherapeutic impact or to provide
20 sensitization or augmentation for radiation treatment (Ranney, D.F., PCT WO 90/03190, filed September 29, 1989, p. 51). It is known that the RME-type polysaccharide arabinogalactan can be used to target certain diagnostic agents, particularly superparamagnetic iron oxide. Menz,
25 E.T., PCT WO 90/01295, filed August 3, 1988.

Therapeutic agents, on the other hand, have been typically targeted by liposomes and glycoproteins. Normally after injection, liposomes are recognized as particulate matter and are subject to phagocytosis, which results in
30 their concentration in the tissues of the reticuloendothelial system (RES). Materials within liposomes are then concentrated in tissues such as the liver, spleen and bone which comprise the RES. Surface-modified liposomes have been synthesized and can be cleared
35 by RME, but the surface modification consisted of a coating of proteins or glycoproteins. Ranade, V.V., 29 J. Clin. Pharmacol. (1989) pp. 685-694; Dragsten et al., 926 Biochem.

- 4 -

Biophys. Acta (1987) pp. 270-279.

Colloids and particles of differing sizes and compositions are recognized by the RES. For example, Inferon, a dextran coated colloidal ferric oxyhydroxide used for the treatment of anemia, is slowly cleared from the blood by the phagocytic activity of the macrophages of the RES. Henderson et al., 34 Blood (1969) pp. 357-375. Radioactive diagnostic agents such as the technicium sulfur colloids and many types of magnetic particles used as MR contrast agents are also cleared by the RES. For a discussion see Josephson et al., 8 Mag. Res. Imag. (1990) pp. 637-646.

Glycoproteins internalized by RME have been used to target therapeutic agents. For a review of targeting strategies see Table II of Meijer et al., 6 Pharm. Res. (1989) pp. 105-118.

Summary of the Invention

The present invention provides a method of targeting a therapeutic agent to a specific population of cells. Targeting may be accomplished by forming a complex between a therapeutic agent and a polysaccharide capable of interacting with receptors performing receptor mediated endocytosis (RME). The resulting complex may then be internalized into the specific population of cells by receptor mediated endocytosis. The invention enables the concentration of therapeutic agents to be increased in tissues where they have beneficial actions and decreased in tissues where they have unwanted, toxic effects. In one embodiment of the invention, the therapeutic agent may include a composition containing iron and the polysaccharide may be arabinogalactan. In this embodiment, a complex of arabinogalactan and a composition containing iron may be formed and used to deliver iron specifically to hepatocytes by RME.

Brief Description of the Drawings

The foregoing features of the invention will be more readily understood by reference to the following detailed

- 5 -

description taken with the accompanying drawings, in which:

Fig. 1 is a graph illustrating the effect of asialofetuin or fetuin on the clearance of an RME-polysaccharide-therapeutic agent complex (in accordance with an embodiment of the invention), to illustrate the specificity of the targeting of this delivery system.

Detailed Description of the Specific Embodiments

General:

The invention provides a method of targeting a therapeutic agent into a specific population of cells. Targeting increases the concentration of the therapeutic agent in cells where the agent exerts some beneficial action and reduces its concentration in other cells where unwanted, toxic effects are being produced. Many therapeutic agents produce toxic effects, not upon the cells where the agent has a beneficial action, but on cells other than those responsible for the beneficial action.

By targeting therapeutic agents towards certain cells, and away from other cells, the invention provides a way of improving the safety and efficacy of previously developed therapeutic agents. For example, a therapeutic agent intended to modify the metabolism of the hepatocytes of the liver, might exhibit toxic effects to bone marrow cells. Since bone marrow function is essential for life, toxic effects on marrow limit the dose of the agent that can be given. If the agent were targeted to hepatocytes by attachment to the arabinogalactan, the concentration to bone marrow would be reduced. The potency of the agent would be improved, because the fraction of the therapeutic agent which normally goes to bone marrow is now directed to the liver. Bone marrow related side effects would be eliminated.

Distinguishing the RME-type Polysaccharides Used by the Invention:

With the current invention, a therapeutic agent is attached to an RME-type polysaccharide and the resulting complex is targeted into specific types of cells through the

action of cell surface receptors. Only certain polysaccharides may be used in the invention and these are termed RME-type polysaccharides. RME-type polysaccharides differ from common, non-RME polysaccharides, e.g., dextrans, 5 dextrans, celluloses, hydroxyethylstarches, heparins, starches, dextran sulfates, carboxymethylated dextran and carboxymethyl cellulose. Non-RME polysaccharides are used in diverse applications such as drug delivery, drug formulation, as food additives and in plasma volume 10 expansion. RME-type polysaccharides include arabinogalactan and mannan, and may be used, according to the invention, to deliver therapeutic agents directly to hepatocytes and macrophages respectively. References, such as Ranney, described above, concerning the delivery of certain 15 therapeutic agents using polysaccharides, do not disclose or concern themselves with the use of RME-type polysaccharides.

Below, we refer to the complex of the invention as the RME-type polysaccharide-therapeutic agent complex. The complex between the RME-type polysaccharide and the 20 therapeutic agent can involve the covalent attachment of the therapeutic agent to the RME-type polysaccharide (Examples 2 and 3), a colloid coated with polysaccharide (Example 1), or a liposome coated with an RME-type polysaccharide.

Chemical modifications of non-RME polysaccharides have 25 been achieved, including carboxymethylation, succinylation, hydroxyethylation and sulfation. Generally, such chemical modification of common polysaccharides does not confer the ability to bind to a receptor and undergo RME.

However, non-RME polysaccharides can, in some 30 instances, be modified by the attachment of substituent groups that are recognized by receptors performing RME, and such modifications confer the property of RME on non-RME polysaccharides. For example, a galactose residue can be attached to the non-RME polysaccharide dextran; the 35 galactose of the resulting polysaccharide will be recognized by the asialoglycoprotein receptor and undergo RME. By attachment of galactose, the dextran is converted into an

RME-type polysaccharide. Similarly, a mannose group can be attached to dextran and the resulting polysaccharide will be recognized by the mannose receptor of phagocytes.

A second modification of RME-type polysaccharides involves partial digestion to produce lower molecular weight polysaccharides. This can be accomplished by controlled hydrolysis with acid and fractionation to obtain RME-type polysaccharides in the desired size class. The polysaccharides of the invention, before degradation or modification, have molecular weights greater than about 1,000 daltons.

For a polysaccharide to be designated an RME-type polysaccharide, its binding to a receptor performing RME must be demonstrated. One type of demonstration involves the ability of an RME-type polysaccharide to block the clearance of a glycoprotein known to be cleared by RME. For example, the interaction of arabinogalactan with the asialoglycoprotein receptor was demonstrated by its ability to block the clearance of a radioactive sample of the asialoglycoprotein, asialofetuin. Injection of 500 mg/kg of arabinogalactan blocks the clearance of ¹²⁵I-asialofetuin in rats. (See Table 1 of Josephson et al., 8 Mag. Res. Imag. (1990) pp. 637-646.) As a result of this experiment as well as others, it can be concluded that arabinogalactan is recognized by the asialoglycoprotein receptor of hepatocytes. Consequently, arabinogalactan is an RME-type polysaccharide.

Similarly, mannan blocks the clearance of radioactive glycoprotein, RNase B. Brown et al., 188 Arch. Biochem. Biophys. (1978) pp. 418-428. Arabinogalactan and mannan are discussed briefly below. In addition to the polysaccharides discussed explicitly herein, other RME-type polysaccharides may be formed as modification or degradation products of the polysaccharides discussed.

A simple test for whether a polysaccharide-therapeutic agent complex is of the type covered by the invention is afforded by the ability of various substances to slow the

- 8 -

elimination of the complex from blood (clearance). The complexes of the invention are cleared by RME, and their clearance is blocked by substances cleared by the same receptor. As shown in Fig. 1, asialofetuin, which is
5 cleared by an RME receptor on hepatocytes, blocks the clearance of the arabinogalactan iron oxide colloid of Example 1. Asialofetuin will not block the clearance of many other colloids or particles coated with surfaces that do not interact with the receptors performing RME.

10 The clearance of the RME-type polysaccharide-therapeutic agent complexes of the invention is unaffected by the injections of substantial concentrations of non-RME type polysaccharides, e.g., dextran and hydroxyethyl starch. The clearance of the RME-polysaccharide-therapeutic agents
15 of the invention is also unaffected by the injection of substantial concentrations of particles, colloids or liposomes cleared by the phagocytic cells of the RES.

Advantages of Polysaccharides as Carriers for the Delivery of Therapeutic Agents:

20 An advantage of using polysaccharides instead of proteins for the delivery of therapeutic agents is that polysaccharides do not denature readily at high temperature, extremes of pH or in organic solvents. In Example 1, the polysaccharide arabinogalactan is used as a coating for an
25 iron oxide colloid. During that synthesis, arabinogalactan is exposed first to a pH below about 3, when soluble iron salts are present, then to a high pH after base addition and finally to a high temperature. Because of the stability of polysaccharides, covalent linkages between therapeutic
30 agents and polysaccharides can be achieved in organic solvents. This is a considerable advantage since some therapeutic agents have low water solubility. A related advantage of polysaccharides working in nonaqueous media is that water unstable linkages like esters can be created
35 between the therapeutic agent and the polysaccharide. An example of such chemistry is provided in Example 3.

Another advantage of polysaccharides is that they can

- 9 -

be obtained from microbiological or plant sources.

Glycoproteins from human or animal sources may contain pathogens whose absence is costly to assure.

Polysaccharides from microbiological or plant sources can be
5 selected for use in the invention which are of very low
toxicity and immunogenicity. Plant or microbiological
sources can provide crude polysaccharide preparations on a
large scale, in a reliable manner and at a reasonable price.
Two classes of carbohydrates which can be utilized in the
10 invention are the arabinogalactans and the mannans.

Arabinogalactans:

Arabinogalactans are a class of polysaccharides that
may be obtained from the cell walls of many species of trees
and plants. A common source of arabinogalactan is the
15 American western larch (*Larix occidentalis*).

Arabinogalactan from this source is used as a binder,
emulsifier or stabilizer in foods. It consists of a
galactose backbone with branch chains of arabinoses and
galactose. Generally, the ratio of galactose to arabinose
20 is between 5:1 and 10:1. The molecular weight can be
between 10 to 100 kilodaltons. Glickman, ed., "Food
Hydrocolloids," CRC Press (1982) pp. 5, 33.

Best results are obtained when a purified
arabinogalactan is used. Commercially available
25 arabinogalactan can be further purified by ultrafiltration
to remove impurities greater than 100,000 daltons and
smaller than 10,000 daltons. Arabinogalactan purified by
this method is used in the examples of the patent. The
arabinogalactan used in Examples 1-3 was subjected to
30 purification in this manner.

Arabinogalactans bind to the asialoglycoprotein
receptor of hepatocytes. This receptor performs RME on a
variety of substances. Harford et al., Vol. IV "The
Glycoconjugates," M.I. Horowitz, ed., Academic Press (1982)
35 pp. 27-55. Therapeutic agents attached to arabinogalactan
will be targeted to hepatocytes.

Mannans:

Mannans are a class of polysaccharides that can be obtained from the cell walls of yeasts. They are predominantly α -D-mannopyrans with a variety of linear and branched chain structures. Gorin et al., Vol. 2 "The Polysaccharides," G.O. Aspinall, ed., Academic Press (1983) pp. 376-380.

Mannans bind to the mannose receptor found on the macrophages of the RES. Therapeutic agents attached to mannan will be targeted to macrophages.

Therapeutic Agents Targeted by the Invention:

Utilizing the methods of the invention, a wide variety of therapeutic agents may be targeted to a population of cells. Examples of such therapeutic agents are listed in Table 1. Some of the agents in Table 1 may be targeted to hepatocytes, such as antiviral agents for the treatment of hepatitis. Iron may be targeted to hepatocytes to remedy nutritional imbalance, i.e., iron deficiency anemia. When genetic defects are expressed in the liver, such as the deficiency of a hepatic enzyme, DNA may be targeted to the liver to alter the genetic defects. The invention may be used to target therapeutic agents that have been targeted by other techniques. Other summaries of therapeutic agents whose targeting has been attempted are available. See Table II of Meijer et al., 6 Pharm. Res. (1989) pp. 105-118 and Ranade, 29 J. Clin. Pharmacol. (1989) pp. 685-694.

**Table 1: Applications and Agents
Targeted by the Invention**

	Agent	Application	Reference
5	Iron	treatment of anemia	Example 1
10	Ara A-phosphate	hepatitis treatment	Bodmer et al., 112 Methods in Enzymology (1985) pp. 298-306
	Triflour-Thymidine	hepatitis treatment	above
15	DNA	genetic defect reversal	Wu et al., 263 J. Biol. Chem. (1988) pp. 14621-14624
20	Metho-trexate	treatment of leishmaniasis	Mukhopadhyay et al., 244 Sci. (1989) pp. 705-707

25 The targeting of antiviral agents into hepatocytes of an individual chronically infected with the hepatitis B virus, is an application of the invention where antiviral agents would be the therapeutic agents targeted. The targeting of an antiviral agent to the infected cell

30 population (hepatocytes), and away from bone marrow, may result in more effective treatment with the drug. Antiviral agents may be attached to arabinogalactan, and injected intravenously, to achieve a high concentration in the hepatocytes. The targeting of nutritionally required

35 substances such as iron may be targeted by the invention. In Example 1, an arabinogalactan colloid is synthesized which targets iron by RME in accordance with the teachings of the present invention. Parenterally administered iron has often been used in the treatment of anemia, in the form

40 of an iron oxide dextran complex called Imferon. The iron oxide dextran is slowly removed from blood by the RES. Imferon exhibits some tendency to produce adverse reactions. Hamstra et al., 243 JAMA (1980) pp. 1726-1731. In contrast, iron oxides made with arabinogalactan (see Example 1) are

45 rapidly cleared by RME and targeted to the hepatocytes of

- 12 -

the liver. This difference in pharmacokinetics and biodistribution may result in the iron of the invention being a safer therapeutic agent than iron oxide dextran.

Vitamins may also be targeted by the invention.

- 5 Example 2 shows the preparation of a folic acid arabinogalactan conjugate, which would target the vitamin folic acid to hepatocytes via RME. Folic acid is chemically similar to the drug methotrexate, which can be coupled to arabinogalactan by minor modifications of the procedure
10 shown for folic acid.

- Hormones such as steroids may be delivered directly to a specific population of cells utilizing the methods of the invention. Steroids have powerful biological activities which are exerted after the steroid binds to a receptor
15 present on the cells. Martin, C.R., "Textbook of Endocrine Physiology," Williams & Wilkins (1976) p. 21. The targeting of steroids to cells is a widely useful application of the invention. One application of targeting hormones involves targeting glucocorticoid steroids into cells. Example 3
20 presents a synthesis of an arabinogalactan-prednisone conjugate which may serve to target the steroid prednisone via RME into hepatocytes. Steroids could be targeted by attachment to mannan, and targeted into appropriate cells by the mannose receptor present on cells of the RES.

25

Examples

Example 1:

- A colloidal iron oxide coated with arabinogalactan was prepared for the treatment of iron deficiency. An arabinogalactan coated superparamagnetic (or paramagnetic)
30 iron oxide as in Example 6.10.1 of WO 90/01295 was prepared. An aqueous solution of FeCl_3 (15.8 g, 58.5 mole) and $\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$ (6.24, 31.6 mmoles) is prepared and filtered through a 0.22 micron filter to remove large debris. Equal volumes of iron salts and a solution of arabinogalactan from larch wood
35 (60 g, Sigma Chemical Co.) in distilled H_2O (120 mL) are combined at ambient temperature with vigorous stirring. A 30% aqueous ammonium hydroxide solution is then added to the

- 13 -

mixture, slowly and dropwise, until the pH reaches about 10. The mixture is then heated to a temperature of about 90-100°C for about 15 minutes. The mixture is allowed to cool and filtered through filters of decreasing porosity of 0.80, 0.45 and 0.22 microns.

Excess arabinogalactan is then removed by ultrafiltration step using a 2 liter hollow fiber unit having a 300 kilodalton cutoff (Amicon, Inc., Danvers, MA). The filtered product from the preceding step is loaded into the ultrafiltration unit and washed by the addition of a buffer of 25 mM sodium citrate (pH 8.5). The washing is repeated about 5 times or until a clear eluent is observed. The washed product is then concentrated back to the initial volume of polysaccharide plus metal solutions.

Because the polysaccharide arabinogalactan has been used as a coating for the iron colloid, it is cleared by the asialoglycoprotein receptor of hepatocytes. The presence of injected iron in the liver, and not in the spleen, indicates the targeting of iron into a specific cell population (hepatocytes) has been achieved. For data see Table 2 of Josephson et al., 8 Mag. Res. Imag. (1990) pp. 637-646 or Table V of Menz et al., PCT WO 90/01295.

The therapeutic potential of the arabinogalactan coated iron oxide is shown when ^{59}Fe is used in the synthesis. The iron is incorporated over a period of days into normal body iron pools, such as the iron found in hemoglobin. Hence, an arabinogalactan form of iron oxide could be a therapeutic agent when used in the treatment of iron deficiency anemia.

Example 2:

Folic acid is a vitamin which has been coupled to a polysaccharide undergoing RME called arabinogalactan as described below. The drug methotrexate is a folic acid antagonist and anticancer drug. Methotrexate may be attached to polysaccharides undergoing RME and used in drug delivery applications, by modifying the folic acid coupling chemistry shown below.

Folic acid dihydrate (6.0 mg, 13 μmol) was suspended in

- 14 -

H₂O (1 mL). NaOH (0.10 N, 7 drops) was added until the white solid folic acid was almost completely dissolved. Purified arabinogalactan (23,000 daltons, 35.3 mg, 1.53 μ mol) was added, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (51.2 mg, 286 μ mol). After stirring for 2.5 hours at room temperature, the reaction mixture was analyzed by HPLC on a Sephadex G-25 column (9.5 X 300 mm) using an eluent of 0.05% NaN₃ (0.33 mL/min). Detection of free and coupled folic acid was accomplished by using a UV detector, set at 280 nm (for folic acid, UV_{max} = 283 nm, log = 4.40). The chromatogram showed a peak with a retention time of 16.8 minutes due to folate conjugated to arabinogalactan. Free folic acid appeared at 35 minutes. These assignment were obtained from chromatographing arabinogalactan and folic acid. Purified arabinogalactan required a refractive index detector as it does not absorb at 280 nm. Based on UV detection, 37% of the folic acid was coupled to arabinogalactan. Based on no loss of folate/arabinogalactan ratio of 3:1 was obtained.

Example 3:

Steroids are a class of drugs which can be delivered to cells by attaching them to polysaccharides that undergo RME. A variety of steroids may be coupled to such polysaccharides following analogous chemistry to that given below. The general steps are (i) preparation of a polysaccharide conjugate providing carboxyl groups by reaction with DTPA, and (ii) attachment of the steroid through the carboxyl group of the DTPA-polysaccharide.

30 Preparation of Arabinogalactan-DTPA:

Purified arabinogalactan (23,000 daltons, 0.50 g, 21.7 μ mol) and diethylenetriaminepentaacetic acid (DTPA) dianhydride (0.102 g, 285 μ mol) were dissolved in DMSO (20 mL) at 60°C. After one hour, the clear solution was cooled to room temperature. Upon addition of H₂O (10 mL), a white precipitate formed. The mixture was filtered on an Amicon YM 5 ultrafiltration membrane (5,000 dalton cutoff), and

- 15 -

washed with H₂O (4 X 30 mL). The product remaining on the membrane was dissolved in H₂O (10 mL), frozen and lyophilized. Yield of white powder: 0.44 g. The nominal DTPA/arabinogalactan ration was 13:1, assuming attachment of all DTPA added (nominal formula weight: 28,000 daltons).

Coupling 6 α -Methylprednisolone to arabinogalactan-DTPA:

Arabinogalactan-DTPA (107.5 mg, 3.8 μ mole) and 6 α -methylprednisolone (64.5 mg, 172 μ mol) were dissolved in DMSO (15 mL) at 60°C. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (259 mg, 1.45 mmol) was added and the reaction mixture allowed to stir at 60°C for one hour. HPLC analysis (Sephadex G-10 column of 9.5 X 300 mm with an eluent of 0.05% NaN₃, 0.50 mL/min, 280 nm UV detector) of the reaction mixture showed only a single peak at 10.5 minutes retention time corresponding to the mobility of the arabinogalactan-DTPA conjugate. No peak from 6 α -methylprednisolone at 19.5 minutes was observed, indicating complete attachment (by esterification) of the steroid to the arabinogalactan-DTPA conjugate. After addition of H₂O (10 mL), the reaction mixture was ultrafiltered using an Amicon YM 3 (3,000 dalton cutoff) and washed with H₂O (3 X 30 mL). The filtrate contained unreacted steroid, carbodiimide, traces of DTPA and other low molecular weight materials. HPLC analysis of the filtrate confirmed the absence of free steroid. H₂O (10 mL) was added to the retentate and the product lyophilized. Yield of off-white powder: 0.10 g.

- 16 -

What is claimed is:

1. A method for the targeting of a therapeutic agent to a specific population of cells comprising:
 - (i) forming a complex of the therapeutic agent with a polysaccharide capable of interacting with a cell receptor; and
 - (ii) allowing the complex to be internalized into the specific population of cells by receptor mediated endocytosis.
2. A method according to claim 1, wherein the polysaccharide, before degradation or modification, has a molecular weight greater than 1,000 daltons.
3. A method according to claim 1, wherein step (i) includes the steps of:
 - (a) obtaining a first polysaccharide and forming a modification thereof, constituting a second polysaccharide that is capable of interacting with a cell receptor; and
 - (b) forming a complex of the therapeutic agent with the second polysaccharide.
4. A method according to claim 3, wherein in step (a), the step of forming a modification of the first polysaccharide includes the step of forming a degradation product of the first polysaccharide, constituting the second polysaccharide that is capable of interacting with a cell receptor.
5. A method according to claim 1, wherein the polysaccharide is selected from the group consisting of arabinogalactan, mannan and fucoidan.
6. A method according to claim 5, wherein the therapeutic agent includes a composition containing iron and the polysaccharide is arabinogalactan.
7. A method according to claim 5, wherein the therapeutic agent includes methotrexate and the polysaccharide is arabinogalactan.
8. A method according to claim 5, wherein the therapeutic agent includes folic acid and the polysaccharide is arabinogalactan.

- 17 -

9. A method according to claim 5, wherein the therapeutic agent includes ara A-phosphate and the polysaccharide is arabinogalactan.

10. A method according to claim 5, wherein the therapeutic agent includes a 6 α -methylprednisolone and the polysaccharide is arabinogalactan.

11. A method according to claim 5, wherein the therapeutic agent includes triflourthymidine and the polysaccharide is arabinogalactan.

12. A method according to claim 1, wherein the therapeutic agent includes a hormone.

13. A method according to claim 12, wherein the hormone is corticosteroid.

14. A method according to claim 12, wherein the hormone is 6 α -methylprednisolone.

15. A method according to claim 1, wherein the therapeutic agent includes a gene.

16. A method according to claim 1, wherein the therapeutic agent includes an enzyme.

17. A method according to claim 1, wherein the therapeutic agent includes a vitamin.


18. A method according to claim 17, wherein the vitamin is folic acid.

19. A method according to claim 1, wherein the therapeutic agent includes a liposome.

20. A method according to claim 15, wherein the polysaccharide is arabinogalactan.

1/1

FIG. 1



SUBSTITUTE SHEET

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 47/48		(11) International Publication Number: WO 92/11037
A3		(43) International Publication Date: 9 July 1992 (09.07.92)
(21) International Application Number: PCT/US91/09368 (22) International Filing Date: 13 December 1991 (13.12.91) (30) Priority data: 630,017 19 December 1990 (19.12.90) US (71) Applicant: ADVANCED MAGNETICS INC. [US/US]; 61 Mooney Street, Cambridge, MA 02138 (US). (72) Inventors: JOSEPHSON, Lee ; 14 Churchill Avenue, Arlington, MA 02174 (US). GROMAN, Ernest, V. ; 80 Columbia Street, Brookline, MA 02135 (US). JUNG, Chu ; 21 Coolidge Road, Arlington, MA 02174 (US). LEWIS, Jerome, M. ; 273 Upland Avenue, Newton, MA 02161 (US).		(74) Agents: SUNSTEIN, Bruce, D. et al.; Bromberg & Sunstein, 10 West Street, Boston, MA 02111 (US). (81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), NO, SE (European patent). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 6 August 1992 (06.08.92)

(54) Title: TARGETING OF THERAPEUTIC AGENTS USING POLYSACCHARIDES



(57) Abstract

The invention relates to a method for the targeting of a therapeutic agent to a specific population of cells, wherein a complex is formed between the therapeutic agent and a polysaccharide capable of interacting with a cell receptor, and wherein the resulting complex is internalized into the cell by receptor mediated endocytosis (RME). In one embodiment of the invention, a complex of a therapeutic agent containing iron and the polysaccharide arabinogalactan may be formed and used to deliver iron specifically to hepatocytes by RME.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 91/09368

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl.5 A 61 K 47/48		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl.5	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ^o	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	WO,A,9001295 (ADVANCED MAGNETICS INC.) 22 February 1990, see page 8, line 31 - page 25, line 32 (cited in the application) ---	1-9,11, 15-20
Y	Magnetic Resonance Imaging, vol. 8, no. 5, 1990, (Elmsford, NY, US), L. JOSEPHSON et al.: "A functionalized superparamagnetic iron oxide colloid as a receptor directed MR contrast agent", pages 637-646, see whole article, and in particular page 644, last paragraph - page 645, paragraph 1 (cited in the application) ---	1-9,11, 15-20
Y	J. American medical Association, vol. 243, no. 17, 2 May 1980, (Chicago, IL, US), R.D. HAMSTRA et al.: "Intravenous iron dextran in clinical medicine", pages 1726-1731, see page 1726, abstract (cited in the application) --- -/-	1-6
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>^o Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
16-04-1992		23 JUN 1992
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		Mme N. KUIPER

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	Science, vol. 244, 12 May 1989, (Washington, DC, US), A. MUKHOPADHYAY et al.: "Receptor-mediated drug delivery to macrophages in chemotherapy of Leishmaniasis", pages 705-707, see page 705, abstract (cited in the application) ---	1-5,7
Y	Pharmaceutical Research, vol. 6, no. 2, 1989, (Stuttgart, DE), D.K.F. MEIJER et al.: "Covalent and noncovalent protein binding of drugs: Implications for hepatic clearance, storage, and cell-specific drug delivery", pages 105-118, see page 105, abstract; page 113, table II (cited in the application) ---	1-5,8,9 11,15- 18,20
Y	The Journal of Biological Chemistry, vol. 263, no. 29, 15 October 1988, (Baltimore, US), G.Y. WU et al.: "Receptor-mediated gene delivery and expression in vivo", pages 14621-14624, see page 14621, abstract (cited in the application) ---	1-5,15, 20
Y	Carbohydrate Research, vol. 118, 1983, (Amsterdam, NL), M.M. PONPIPOM et al.: "Synthesis of 6-(5-cholesten-3beta-yloxy)hexyl 4-O-(6-deoxy-beta-D-galactopyranosyl)-1-thio-beta-D-glucopyranoside and derivatives thereof for in vivo liposome studies", pages 47-55, see page 47, paragraph 1 - page 48, paragraph 1 ---	1-5,19
Y	Biochemistry International, vol. 10, no. 3, March 1985, (North Ryde, AU), P. DASGUPTA et al.: "Receptor-mediated uptake of asialoganglioside liposomes: Sub-cellular distribution on the liposomal marker in isolated liver cell types", pages 327-338, see page 327, summary ---	1-5,19
Y	Proc. Indian. natn. Sci. Acad., vol. 48, supplement no. 1, 1982, (New Delhi, IN), P. GHOSH et al.: "An approach to tissue targeting of drugs and proteins using liposomes", pages 12-19, see page 12, abstract ---	1-5,19
Y	Methods in Enzymology, vol. 112, 1985, (New York, US), J.L. BODMER et al.: "[23] Carrier potential of glycoproteins", pages 298-306, see page 298, paragraph 2; page 302, paragraph 2 (cited in the application) ---	1-5,9, 11
A	EP,A,0281809 (AMERICAN CYANAMID CO.) 14 September 1988, see page 2, lines 16-18,32-50 -----	

Form PCT/ISA/210 (extra sheet) (January 1983)

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claim numbers _____ because they relate to subject matter not required to be searched by this Authority, namely:
 Remark: Where the claims relate to an invivo method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claim numbers _____ because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim numbers _____ because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This international Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims: _____
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers: _____
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9109368

SA 55503

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 17/06/92.
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 9001295	22-02-90	EP-A- 0381742	16-08-90
		JP-T- 4501218	05-03-92
EP-A- 0281809	14-09-88	US-A- 4857505	15-08-89
		AU-B- 603189	08-11-90
		AU-A- 1277688	08-09-88
		JP-A- 63253030	20-10-88
		ZA-A- 8801657	06-09-88

EPO FORM 1047

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82